Mechanistic Studies of Psilocybin in Headache Disorders
In previous clinical trial work, the investigators observed lasting reductions in headache burden after limited dosing of psilocybin. This purpose of this study is to examine potential sources for this observed effect. This study will measure brain resting state functional connectivity (fMRI), central synaptic density (SV2A PET), peripheral markers of inflammation, circadian rhythm (actigraphy), and sleep (sleep EEG) in both migraine and healthy control participants before and one week after the administration of psilocybin or an active control agent.
- Status
- recruiting
- Phase
- Early Phase 1
- Institution
- Yale University
- Start date
- 2025-05-19
- End date
- 2027-12-31
- Registry ID
- NCT06464367
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.